STOCK TITAN

VistaGen Therapeutics Inc - VTGN STOCK NEWS

Welcome to our dedicated news page for VistaGen Therapeutics (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on VistaGen Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VistaGen Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VistaGen Therapeutics's position in the market.

Rhea-AI Summary
Vistagen (Nasdaq: VTGN) will present at the TD Cowen 44th Annual Health Care Conference, with CEO Shawn Singh giving a corporate overview on March 6, 2024. Investors can arrange one-on-one meetings through their Cowen representative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences
-
Rhea-AI Summary
Vistagen reports financial results for Q3 2024 and updates on PALISADE Phase 3 program for social anxiety disorder treatment. Initiates trials for fasedienol and progresses itruvone and PH80 development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
earnings
-
Rhea-AI Summary
Vistagen (NASDAQ: VTGN) will host a conference call and webcast on February 13, 2024, to report results for its fiscal year 2024 third quarter and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
conferences earnings
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announced positive preclinical and Phase 1 clinical data for AV-101, a potential treatment for neuropathic pain, with a favorable safety profile. The European Patent Office issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain, adding to Vistagen's global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
none
-
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) reports positive Phase 3 results for fasedienol in the treatment of social anxiety disorder (SAD), with preparations underway for potential NDA-enabling Phase 3 studies in 2024. The company secured $137.7 million in gross proceeds, including $100 million from an underwritten public offering of equity securities, strengthening its financial position for future developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.07%
Tags
earnings
-
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announces participation in Stifel 2023 Healthcare Conference to present corporate overview and host one-on-one meetings, offering webcast accessibility through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.49%
Tags
conferences
Rhea-AI Summary
Vistagen (Nasdaq: VTGN) announces positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial for social anxiety disorder and Phase 2A study for vasomotor symptoms, with plans to initiate a Phase 3 clinical trial for SAD in early 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
conferences clinical trial
-
Rhea-AI Summary
Vistagen (NASDAQ: VTGN) will host a conference call and webcast on November 9, 2023, to provide a corporate update and report results for its fiscal year 2024 second quarter. The event will start at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Participants can access the webcast via the provided link and a telephone playback will be available after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences earnings
-
Rhea-AI Summary
Vistagen to present and host meetings at Jefferies Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.04%
Tags
conferences
Rhea-AI Summary
Vistagen Therapeutics announces pricing of $100 million underwritten offering of its common stock and warrants, led by BVF Partners LP and other institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.85%
Tags
none
VistaGen Therapeutics Inc

Nasdaq:VTGN

VTGN Rankings

VTGN Stock Data

137.02M
15.25M
0.17%
65.44%
6.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About VTGN

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.